0001562180-23-003442.txt : 20230405
0001562180-23-003442.hdr.sgml : 20230405
20230405163611
ACCESSION NUMBER: 0001562180-23-003442
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230403
FILED AS OF DATE: 20230405
DATE AS OF CHANGE: 20230405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Mark Douglas
CENTRAL INDEX KEY: 0001756253
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38977
FILM NUMBER: 23803093
MAIL ADDRESS:
STREET 1: C/O TELADOC HEALTH, INC.
STREET 2: 2 MANHATTANVILLE ROAD, SUITE 203
CITY: PURCHASE
STATE: NY
ZIP: 10577
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phreesia, Inc.
CENTRAL INDEX KEY: 0001412408
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0131
BUSINESS ADDRESS:
STREET 1: 1521 CONCORD PIKE
STREET 2: SUITE 301 PMB 221
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 888-654-7473
MAIL ADDRESS:
STREET 1: 1521 CONCORD PIKE
STREET 2: SUITE 301 PMB 221
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: Phreesia Inc
DATE OF NAME CHANGE: 20070914
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-04-03
false
0001412408
Phreesia, Inc.
PHR
0001756253
Smith Mark Douglas
C/O PHREESIA, INC.
1521 CONCORD PIKE, SUITE 301 PMB 221
WILMINGTON
DE
19803
true
false
false
false
true
Common Stock
2023-04-03
4
M
false
7000.00
4.71
A
23112.00
D
Common Stock
2023-04-03
4
S
false
6500.00
30.6895
D
16612.00
D
Common Stock
2023-04-03
4
S
false
500.00
31.771
D
16112.00
D
Stock Option
4.71
2023-04-03
4
M
false
7000.00
0.00
D
2028-09-04
Common Stock
7000.00
65193.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 18, 2023.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.33 to $31.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $31.93 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
27,306 of the original 84,193 shares underlying the option vested became exercisable on September 5, 2019, with 25% of the remainder vesting on September 5, 2019, and 75% of the remainder vesting in thirty-six (36) equal monthly installments thereafter.
/s/ Alexis Lyons, as Attorney-in-Fact for Smith Mark Douglas
2023-04-05